15-HYDROXYEICOSATETRAENOIC ACID AND DIABETIC ENDOTHELIAL DYSFUNCTION IN RABBIT AORTA

Citation
B. Tesfamariam et al., 15-HYDROXYEICOSATETRAENOIC ACID AND DIABETIC ENDOTHELIAL DYSFUNCTION IN RABBIT AORTA, Journal of cardiovascular pharmacology, 25(5), 1995, pp. 748-755
Citations number
35
Categorie Soggetti
Cardiac & Cardiovascular System","Respiratory System","Pharmacology & Pharmacy
ISSN journal
01602446
Volume
25
Issue
5
Year of publication
1995
Pages
748 - 755
Database
ISI
SICI code
0160-2446(1995)25:5<748:1AADED>2.0.ZU;2-M
Abstract
We examined the effects of diabetes on eicosanoid metabolism and endot helium-dependent relaxation in isolated aorta from alloxan-induced dia betic rabbits and that from normal rabbits incubated in increased conc entrations (44 mM) of glucose in vitro for 6 h. Immunoreactive 15-hydr oxyeicosatetraenoic acid (HETE) was assayed in the incubation media of isolated aortic segments. Basal and acetylcholine (ACh)-stimulated re lease of 15-HETE was significantly greater in aorta of diabetic animal s as compared with those of normal rabbits. Incubation of aortic segme nts from normal rabbits in increased concentrations of glucose caused a significant increase in basal and ACh-stimulated release of 15-HETE; and the release was significantly greater in aortic segments with end othelium than in segments without endothelium. Basal and ACh-stimulate d release of 15-HETE was inhibited by indomethacin, a cyclooxygenase i nhibitor. 15-HETE caused contractions of aortic rings that were inhibi ted by the prostaglandin H-2 (PGH(2)) thromboxane A(2) (TXA(2)) recept or blocker SQ-29548, but not by the TXA(2) synthase inhibitor carbetho xyhexyl imidazole or indomethacin. Treatment of aortic rings with subt hreshold concentrations of 15-HETE impaired ACh-induced relaxation; th is was prevented by treatment with SQ-29548. Thus, abnormal release of endothelium-derived 15-HETE may play a role in endothelial cell dysfu nction and increased vasoconstriction in diabetes by a mechanism that involves interaction with PGH(2)/TXA(2) receptors.